Entera Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>EB</div>
ENTX -- USA Stock  

USD 2.89  0.05  1.70%

While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to break down Entera Bio. We will try to explain if it is still possible for Entera Bio to generate above-average margins. Is Entera Bio valuation justified? I am going to cover the entity perspective on valuation to give you a better outlook on taking a position in it.
Published over a month ago
View all stories for Entera Bio | View All Stories
Is Entera Bio (NASDAQ:ENTX) ready for a correction?
Entera Bio currently holds 216 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the firm is not taking enough advantage from borrowing. This firm has a current ratio of 2.62, suggesting that it is liquid enough and is able to pay its financial obligations when due.
We provide trade advice to complement the prevailing expert consensus on Entera Bio. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Entera Bio using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Entera Bio based exclusively on its fundamental and basic technical indicators. By analyzing Entera Bio's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Entera Bio's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Entera Bio. We calculate exposure to Entera Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Entera Bio's related companies.

Entera Bio Investment Alerts

Entera investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Entera Bio performance across your portfolios.Please check all investment alerts for Entera

Entera Bio Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Entera value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Entera Bio competition to find correlations between indicators driving the intrinsic value of Entera.

How Entera utilizes its cash?

To perform a cash flow analysis of Entera Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Entera Bio is receiving and how much cash it distributes out in a given period. The Entera Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Entera Bio Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Entera Bio reported Net Cash Flow from Operations of (10.42 Million) in 2020

Detailed Perspective On Entera Bio

The current price rise of Entera Bio could raise concerns from investors as the firm it trading at a share price of 6.90 on 124,049,778 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in April. The stock standard deviation of daily returns for 30 days investing horizon is currently 22.19. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Entera Bio partners.

Margins Breakdown

Entera profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Entera Bio itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Entera Bio profit margins.
EBITDA Margin(43.44)
Gross Margin0.1
Profit Margin(44.42)


Entera Bio Earnings before Tax is fairly stable at the moment. Entera Bio Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 6 years. The current value of Entera Bio Earnings Before Interest Taxes and Depreciation Amortization EBITDA is -10,251,403. Additionally, Entera Bio Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 6 years. The current value of Entera Bio Earnings Before Interest Taxes and Depreciation Amortization USD is -10,251,403. Entera Bio Earnings before Tax is decreasing over the last 6 years. The current value of Entera Bio Earnings before Tax is -10,482,513. Entera Bio Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 6 years. The current value of Entera Bio Earnings Before Interest Taxes and Depreciation Amortization EBITDA is -10,251,403. Additionally, Entera Bio Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 6 years. The previous year's value of Entera Bio Earnings Before Interest Taxes and Depreciation Amortization USD was -10,251,403.

Our perspective of the current Entera Bio rise

Current treynor ratio is at 0.96.
As of the 12th of March 2021, Entera Bio shows the Mean Deviation of 7.41, coefficient of variation of 648.37, and Downside Deviation of 5.2. Entera Bio technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Entera Bio, which can be compared to its rivals. Please confirm Entera Bio variance and potential upside to decide if Entera Bio is priced favorably, providing market reflects its regular price of 6.9 per share. Given that Entera Bio has jensen alpha of 2.71, we urge you to verify Entera Bio's prevailing market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Entera Bio

While some other companies under the biotechnology industry are still a bit expensive, Entera Bio may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Entera valuation and our trade advice on Entera Bio is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Entera Bio.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Entera Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com